Publicité
Publicité
GANX
Gain Therapeutics, Inc. Common Stock
2.30
USDSponsorisé
-0.14
-5.78%
09 janv., 15:59 UTC -5
Fermé
Après-marché
2.35
+0.06
+2.44%
GANX Rapports sur les bénéfices
Ratio de surprise positive
GANX a dépassé 10 des 19 dernières estimations.
53%
Prochain rapport
Date du prochain rapport
25 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.14
Variation implicite de Q3 25 (Revenue/ EPS)
--
/-6.67%
Variation implicite de Q4 24 (Revenue/ EPS)
--
/+27.27%
Gain Therapeutics, Inc. Common Stock earnings per share and revenue
On 12 nov. 2025, GANX reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.15 USD, resulting in a 1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +10.07% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analystes forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an baisse of -6.67% EPS, and hausse of 0.00% in Revenue from the last quarter.
FAQ
What were Gain Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Gain Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 1.96%, and revenue of $0.00, 0% as expectations.
How did the market react to Gain Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 10.07%, changed from $2.68 before the earnings release to $2.95 the day after.
When is Gain Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 25 mars 2026.
What are the forecasts for Gain Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analystes, Gain Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité